Lactacystin

Induces neuritogenesis. Potent and selective irreversible proteasome inhibitor. Specifically inhibits 20S proteasome (MCP; multicatalytic complex). Blocks proteasome activity by targeting the catalytic beta-subunit. Apoptosis inducer. Anticancer compound. Upregulates HSP70 and HSP22. Induces differentiation and inhibits cell cycle progression in several tumor cell lines. Inhibits NF-kappaB activation by inhibiting IkappaB degradation. Cathepsin A inhibitor. gamma-Secretase activity inhibitor. Anti-adipogenic.\n\nStorage and Stability:\nShort-term Storage: +4 degrees C\nLong-term Storage: -20 degrees C\nStable for at least 3 years after receipt when stored at -20 degrees C.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

044983

Size

100ug

Purity

>98% (HPLC)

References

Product Reference: \n?Lactacystin, a novel microbial metabolite, induces neuritogenesis of neuroblastoma cells: S. Omura, et al.; J. Antibiot. (Tokyo) 44, 113 (1991)\n?Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin: G. Fenteany, et al.; Science 268, 726 (1995)\n?Structure-activity relationships of lactacystin, the first non-protein neurotrophic factor: T. Nagamitsu, et al.; J. Antibiot. (Tokyo) 48, 747 (1995)\n?Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells: S. Imajoh-Ohmi, et al.; BBRC 217, 1070 (1995)\n?Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation: A. Craiu, et al.; J. Biol. Chem. 272, 56 (1997)\n?The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis: J. Delic, et al.; Br. J. Cancer 77, 1103 (1998)\n?Lactacystin, proteasome function, and cell fate: G. Fenteany & S.L. Schreiber; J. Biol. Chem. 273, 8545 (1998) (Review) \n?Proteasome inhibitors MG132 and lactacystin hyperphosphorylate HSF1 and induce hsp70 and hsp27 expression: D. Kim, et al.; BBRC 254, 264 (1999)\n?Induction of G1 arrest and selective growth inhibition by lactacystin in human umbilical vein endothelial cells: S.I. Kumeda, et al.; Anticancer Res. 19, 3961 (1999)\n?Lactacystin activates FLICE (caspase 8) protease and induces apoptosis in Fas-resistant adult T-cell leukemia cell lines: Y. Yamada, et al.; Eur. J. Haematol. 64, 315 (2000)\n?Inhibitory and stimulatory effects of lactacystin on expression of nitric oxide synthase type 2 in brain glial cells. The role of Ikappa B-beta: M. Stasiolek, et al.; J. Biol. Chem. 275, 24847 (2000)\n?Lactacystin inhibits cathepsin A activity in melanoma cell lines: L. Kozlowski, et al.; Tumour Biol. 22, 211 (2001)\n?Lactacystin exhibits potent anti-tumor activity in an animal model of malignant glioma when administered via controlled-release polymers: F.G. Legnani, et al.; J. Neurooncol. 77, 225 (2006)\n?Lactacystin decreases amyloid-beta peptide production by inhibiting beta-secretase activity: P. Kienlen-Campard, et al.; J. Neurosci. Res. 84, 1311 (2006)\n?Lactacystin inhibits 3T3-L1 adipocyte differentiation through induction of CHOP-10 expression: X. Li, et al.; BBRC 350, 1 (2006)\n?Inhibition of human preadipocyte proteasomal activity by HIV protease inhibitors or specific inhibitor lactacystin leads to a defect in adipogenesis, which involves matrix metalloproteinase-9: S. De Barros, et al.; J. Pharmacol. Exp. Ther. 320, 291 (2007)\n?